IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

M. Rigdon Lentz

Serial No.:

09/699,003

Art Unit:

3772

Filed:

October 26, 2000

Examiner:

Patricia Bianco

For:

METHOD AND COMPOSITIONS FOR TREATMENT OF CANCERS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. § 1.56 and 37 C.F.R. § 1.97, Applicant submits a Supplemental Information Disclosure Statement, including two (2) pages of Form PTO-1449 and copies of the documents cited therein. Pursuant to the waiver in the notice entitled "Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications Filed After June 30, 2003" published on August 5, 2003 in 1273 OG 55, copies of the U.S. Patents cited below are not enclosed. However, copies will be provided upon request.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(c) after a first Office Action on the merits. The Commissioner is authorized to charge \$180.00, the fee set forth under 37 CFR § 1.17(p), to Account No. 50-3129. It is believed that no additional fee is required with this submission. However, should an additional fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 50-3129.

U.S.S.N.:

09/699,003

Filed:

October 26, 2000

SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT

U.S. Patents

| Number | Issue Date | Patentee Patentee | Class/Subclass |
|-----------|------------|-------------------|----------------|
| 5,621,077 | 04-15-1997 | Novick, et al. | 530/350 |
| 5,792,845 | 08-11-1998 | O'Reilly, et al. | 536/23.1 |
| 6,824,986 | 11-30-2004 | Finkelman, et al. | 435/7.1 |
| 7,196,070 | 03-27-2007 | Sukumar | 514/44 |

Foreign Documents

| <u>Number</u> | Publication Date | <u>Patentee</u> | <u>Country</u> |
|---------------|------------------|-----------------|----------------|
| WO 9100742 | 01-24-1991 | Giri & Horuk | PCT |

Publications

DUMMER, "Circulating interleukin-2 receptors are a group of multimeric proteins with immunoreactivity for interleukin-2 receptor alpha, beta, and gamma chains", *J. Interferon Cytokine Res.*, 16(4):315-320 (1996).

K.A. FITZGERALD, et al., Cytokine Facts Book Second Edition, Academic Press New York, pages 71 and 272 (2001).

LOTEM, et al., "Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemic cells", *Blood*, 80(7):1750-1757 (1992).

NOVICK, "Soluble cytokine receptors are present in normal human urine", *J. Exp. Med.*, 170(4):1409-1414 (1989).

YOUNG, et al., "Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells", *International J. Cancer*, 74(1):69-74 (1997).

U.S.S.N.:

09/699,003

Filed:

October 26, 2000

SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has

been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an

independent evaluation of the cited art to determine its relevance to the subject matter of the

present application. Applicant is of the opinion that his claims patentably distinguish over the art

referred to herein, either alone or in combination.

Respectfully submitted,

/ Patrea L. Pabst /

Patrea L. Pabst

Reg. No. 31,284

Dated: July 15, 2008

PABST PATENT GROUP LLP

400 Colony Square, Suite 1200

1201 Peachtree Street

Atlanta, Georgia 30361

(404) 879-2151 (Telephone)

(404) 879-2160 (Fax)

3